Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b- tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: A novel series of 5-HT2A/2C receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 11, 2004, Pages 2765-2771

  Cid, José ^a   Alonso, José M ^a   Andrés, José I ^a   Fernández, Javier ^a   Gil, Pilar ^a   Iturrino, Laura ^a   Matesanz, Encarna ^a   Meert, Theo F ^b   Megens, Anton ^b   Sipido, Victor K ^b   Trabanco, Andrés A ^a  

^a Johnson Johnson Pharmaceutical R D   (Spain)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Anxiolytics; mCPP antagonist

Indexed keywords

5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; FURAN DERIVATIVE; JNJ 17297709; R 107500; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; TETRAHYDROFURAN DERIVATIVE;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION;

FURANS; HUMANS; LIGANDS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2342643582     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.03.069     Document Type: Article

References (29)

1. Blackburn T.P. Rose F.C. Advances in Neuropharmacology. 1993;51 Smith-Gordon and Nishimura, New York
2. Jones B.J., Blackburn T.P. Pharmacol. Biochem. Behav. 71:2002;555-568
3. Gatch M.B. Life Sciences. 7:2003;1347. and references cited therein
4. Meert T.F., Melis W., Aerts N., Clincke G. Behav. Pharmacol. 8:1997;353-363
5. Bromidge S.M., Dabbs S., Davies D.T., Davies S., Duckworth D.M., Forbes I.T., Gaster L.M., Ham P., Jones G.E., King F.D., Mulholland K.R., Saunders D.V., Wyman P.A., Blaney F.E., Clarke S.E., Blackburn T.P., Holland V., Kennett G.A., Lightowler S., Middlemiss D.N., Trail B., Riley G.J., Wood M.D. J. Med. Chem. 43:2000;1123-1134
6. Martin J.R., Ballard T.M., Higgins G.A. Pharmacol. Biochem. Behav. 71:2002;615-625
7. Bromidge S.M. King F.D. Medicinal Chemistry. 2nd ed. 2002;382-396 The Royal Society of Chemistry, Cambridge UK
8. Di Matteo V., Di Giovanni G., Esposito E. CNS Drug Rev. 6:2000;195-205
9. Higgins G.A., Fletcher P.J. Eur. J. Pharmacol. 480:2003;151-162
10. Wood M.D., Reavill C., Trail B., Wilson A., Stean T., Kennett G.A., Lightowler S., Blackburn T.P., Thomas D., Gager T.L., Riley G., Holland V., Bromidge S.M., Forbes I.T., Middlemiss D.N. Neuropharmacology. 41:2001;186-199
11. Gacsályi I., Schmidt E., Gyertyán I., Vasar A., Haapalinna A., Fekete M., Hietala J., Syvälahti E., Tuomainen P., Männistö P. Drug Dev. Res. 40:1997;333-348
12. Fernández Gadea, F. J.; Sipido, V. K.; Andrés Gil, J. I.; Meert, T. F.; Janssen Pharmaceutica NV Patent Application PCT/EP95/04197; WO96/14321 17 May 1996
13. Andrés J.I., Alcázar J., Alonso J.M., Díaz A., Fernández J., Gil P., Iturrino L., Matesanz E., Meert T.F., Megens A., Sipido V.K. Bioorg. Med. Chem. Lett. 12:2002;243-248
14. Andrés J.I., Alcázar J., Alonso J.M., Díaz A., Fernández J., Gil P., Iturrino L., Matesanz E., Meert T.F., Megens A., Sipido V.K. Bioorg. Med. Chem. Lett. 12:2002;249-253;
15. Andrés J.I., Alonso J.M., Díaz A., Fernández J., Iturrino L., Martínez P., Meert T.F., Sipido V.K. Bioorg. Med. Chem. Lett. 12:2002;3573-3577
16. Andrés J.I., Alcázar J., Alonso J.M., Díaz A., Fernández J., Gil P., Iturrino L., Matesanz E., Meert T.F., Megens A., Sipido V.K., Willems J. Drug Future. 27(Suppl. A):2002;. XVIIth Int. Symp. On Medicinal Chemistry C41
17. De Paulis T., Betts C.R., Smith H.E., Mobley P.L., Manier D.H., Susler F. J. Med. Chem. 24:1981;1021
18. Ueda I., Sato Y., Maeno S., Umio S. Chem. Pharm. Bull. 23:1975;2223
19. MacNeil S.L., Gray M., Briggs L.E., Li J.J., Snieckus V. Synlett. 1998;419
20. 1H NMR spectroscopy of the crude reaction (ca. 10%)
21. Martín S.F., Dodge J.A. Tetrahedron Lett. 32:1991;3017
22. For an alternative synthesis of trans-fused derivatives see: Gil, L.; opetegui, P.; Fernández Gadea, F. J.; Meert, T. F. Janssen Pharmaceutica NV. Patent Application PCT/EP97/01829; WO97/38991 23 October 1997
23. Barluenga J. Pure Appl. Chem. 71:1999;431
24. Begasse B., Le Corre M. Synthesis. 1981;197
25. Leysen J.E., Niemegeers C.J., Van Nueten J.M., Laduron P.M. Mol. Pharmacol. 21:1982;301-304
26. Pazos A., Hoyer D., Palacios J.M. Eur. J. Pharmacol. 106:1985;539-546
27. Hall H., Oegren S.O. Life Sci. 34:1984;597-605
28. All the compounds in Table 1 were assayed as mixtures of either trans-fused (1:1) or cis-fused (3:2) diastereoisomers
29. The relative stereochemistry of the three chiral centres in 16a-d was ascertained by means of 2D-NOESY experiments; the absolute configuration of the enantiomerically pure form has not been determined